U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H29NO4S
Molecular Weight 439.567
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAROGLITAZAR

SMILES

CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)C(O)=O

InChI

InChIKey=MRWFZSLZNUJVQW-DEOSSOPVSA-N
InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H29NO4S
Molecular Weight 439.567
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Saroglitazar, a dual peroxisome proliferator-activated receptor PPAR-α/γ agonist, was an emerging therapeutic option on glycemic and lipid parameters. The Zydus Group has launched LipaglynTM ((Saroglitazar) in India for diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In addition, saroglitazar participated in phase II clinical trials that completed enrolment in patients with primary biliary cholangitis and in patients with non-alcoholic steatohepatitis.

Approval Year

PubMed

PubMed

TitleDatePubMed
Saroglitazar for the treatment of dyslipidemia in diabetic patients.
2015 Mar
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
2018 Dec
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
2018 Jun
Patents

Sample Use Guides

Primary Biliary Cirrhosis: saroglitazar magnesium 2 mg or 4 mg tablet Once daily for 16 weeks Non Alcoholic Steatohepatitis: Saroglitazar Magnesium 2 mg or 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:33:49 UTC 2023
Edited
by admin
on Sat Dec 16 05:33:49 UTC 2023
Record UNII
E0YMX3S4JD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAROGLITAZAR
INN   WHO-DD  
INN  
Official Name English
saroglitazar [INN]
Common Name English
BENZENEPROPANOIC ACID, .ALPHA.-ETHOXY-4-(2-(2-METHYL-5-(4-(METHYLTHIO)PHENYL)-1H-PYRROL-1-YL)ETHOXY)-, (.ALPHA.S)-
Common Name English
(2S)-2-ETHOXY-3-(4-(2-(2-METHYL-5-(4-(METHYLSULFANYL)PHENYL)-1H-PYRROL-1-YL(ETHOXY)PHENYL)PROPANOIC ACID
Common Name English
Saroglitazar [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98233
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
Code System Code Type Description
SMS_ID
100000174930
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID10197819
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
CAS
495399-09-2
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
INN
9677
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
WIKIPEDIA
SAROGLITAZAR
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
CHEBI
134708
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
DRUG CENTRAL
5047
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
NCI_THESAURUS
C152303
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
PUBCHEM
60151560
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
FDA UNII
E0YMX3S4JD
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
DRUG BANK
DB13115
Created by admin on Sat Dec 16 05:33:49 UTC 2023 , Edited by admin on Sat Dec 16 05:33:49 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
sarogli tazar has a predominant affinity for the PPAR-α isoform, and an intermediate affinity for PPAR-γ
TARGET -> AGONIST
sarogli tazar has a predominant affinity for the PPAR-.ALPHA. isoform, and an intermediate affinity for PPAR-.GAMMA.
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY